Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
Subscribe To Our Newsletter & Stay Updated